Hemolytic anemia and benign pelvic tumors - A case report
anemia; Obstetrics & Gynecology; autoimmune; pelvic neoplasms; hemolytic
BACKGROUND: Hemolytic anemia associated with benign pelvic neoplasms is very rare. Sixteen cases have been reported in the English-language literature. CASE: A 27-year-old woman complained of dizziness, fatigue and headache. Physical Examination revealed jaundice and mild tachycardia. Laboratory evaluation indicated intravascular hemolysis, and workups for hematologic and infectious disease etiologies were negative. Multiple blood transfusions and steroids failed. Computed tomography showed a large, complex pelvic mass (10 x 10 x 6 cm). Exploratory laparotomy and excision of bilateral dermoid cysts were performed, and the anemia resolved. The patient was healthy, without recurrence, seven years later. CONCLUSION: It is important to seek to identify pelvic tumors in patients presenting with hemolytic anemia because this condition is often resistant to standard medical therapy and resolves only after removal of the neoplasm. (J Reprod Med 2001;46:401-404).
Buchwalter C L; Miller D; Jenison E L
Journal of Reproductive Medicine
2001
2001-04
Journal Article or Conference Abstract Publication
n/a
Why Don't We Have a Vaccine Against Autoimmune Diseases? - A Review
Autoimmune; Immunotherapy; Multiple sclerosis; Rheumatoid arthritis; Type 1 diabetes; Vaccine
This review examines some of the reasons why we don't have a vaccine against autoimmune diseases and highlights the progress that has been made. Many autoimmune diseases, such as rheumatoid arthritis (RA), multiple sclerosis (MS) and type 1 diabetes (T1D), are driven by autoimmune T cell responses. Unlike vaccines for most infectious diseases, which elicit antibody responses, are intended for immuno-naive individuals and considered preventative, a vaccine for an autoimmune disease must be therapeutic and resolve or control the on-going autoimmune response and condition in the diseased host. Despite these differences, many of the same considerations for infectious disease vaccines must also be addressed to develop a therapeutic vaccine for autoimmune diseases. The disease initiator/triggers, antigens and autoantigens, nature of the immunopathogenic and protective/therapeutic immune response will be compared for infectious and autoimmune diseases as will approaches for developing vaccines including formulations, animal models and indicators of success. The rationale for a therapeutic vaccine for RA will be discussed in greater detail with a relatively limited discussion of T1D, MS and other autoimmune diseases.
Rosenthal Ken S; Carambula Roy; Zimmerman Daniel H
Journal of Clinical & Cellular Immunology
2019
2019
<a href="http://doi.org/10.4172/2155-9899.1000574" target="_blank" rel="noreferrer noopener">10.4172/2155-9899.1000574</a>